WO2019186276A3 - Antibody-based methods of detecting and treating alzheimer's disease - Google Patents

Antibody-based methods of detecting and treating alzheimer's disease Download PDF

Info

Publication number
WO2019186276A3
WO2019186276A3 PCT/IB2019/000358 IB2019000358W WO2019186276A3 WO 2019186276 A3 WO2019186276 A3 WO 2019186276A3 IB 2019000358 W IB2019000358 W IB 2019000358W WO 2019186276 A3 WO2019186276 A3 WO 2019186276A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
detecting
antibody
treating alzheimer
based methods
Prior art date
Application number
PCT/IB2019/000358
Other languages
French (fr)
Other versions
WO2019186276A2 (en
WO2019186276A8 (en
Inventor
Jozef Hanes
Eva Kontsekova
Andrej KOVAC
Norbert ZILKA
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11202008098TA priority Critical patent/SG11202008098TA/en
Priority to EP19732436.1A priority patent/EP3774887A2/en
Priority to JP2020551506A priority patent/JP2021520777A/en
Priority to RU2020135052A priority patent/RU2020135052A/en
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Priority to US15/733,660 priority patent/US20210139568A1/en
Priority to CN201980029711.2A priority patent/CN112236452A/en
Priority to BR112020018868-9A priority patent/BR112020018868A2/en
Priority to CA3095443A priority patent/CA3095443A1/en
Priority to AU2019244481A priority patent/AU2019244481A1/en
Priority to KR1020207030584A priority patent/KR20200144551A/en
Priority to MX2020009991A priority patent/MX2020009991A/en
Publication of WO2019186276A2 publication Critical patent/WO2019186276A2/en
Publication of WO2019186276A3 publication Critical patent/WO2019186276A3/en
Priority to IL277577A priority patent/IL277577A/en
Publication of WO2019186276A8 publication Critical patent/WO2019186276A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are antibodies and antigen binding fragments that bind phosphorylated and dephosphorylated tau and methods of use in detecting and treating Alzheimer's disease and other tauopathies. Also included are methods for determining the stage of Alzheimer's disease in a human subject and monitoring the effectiveness of an anti-tau therapy.
PCT/IB2019/000358 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease WO2019186276A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201980029711.2A CN112236452A (en) 2018-03-28 2019-03-27 Antibody-based methods for detecting and treating alzheimer's disease
JP2020551506A JP2021520777A (en) 2018-03-28 2019-03-27 Antibody-based methods for detecting and treating Alzheimer's disease
RU2020135052A RU2020135052A (en) 2018-03-28 2019-03-27 METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE BASED ON ANTIBODIES
CA3095443A CA3095443A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
US15/733,660 US20210139568A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
EP19732436.1A EP3774887A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
BR112020018868-9A BR112020018868A2 (en) 2018-03-28 2019-03-27 antibody-based methods to detect and treat alzheimer's disease
SG11202008098TA SG11202008098TA (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease
AU2019244481A AU2019244481A1 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating Alzheimer's disease
KR1020207030584A KR20200144551A (en) 2018-03-28 2019-03-27 Antibody-based method for detecting and treating Alzheimer's disease
MX2020009991A MX2020009991A (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease.
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods of detecting and treating alzheimer's disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US62/649,208 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US62/664,662 2018-04-30
US201862703299P 2018-07-25 2018-07-25
US62/703,299 2018-07-25

Publications (3)

Publication Number Publication Date
WO2019186276A2 WO2019186276A2 (en) 2019-10-03
WO2019186276A3 true WO2019186276A3 (en) 2020-02-27
WO2019186276A8 WO2019186276A8 (en) 2020-10-15

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (en)
JP (1) JP2021520777A (en)
KR (1) KR20200144551A (en)
CN (1) CN112236452A (en)
AU (1) AU2019244481A1 (en)
BR (1) BR112020018868A2 (en)
CA (1) CA3095443A1 (en)
IL (1) IL277577A (en)
MX (1) MX2020009991A (en)
RU (1) RU2020135052A (en)
SG (1) SG11202008098TA (en)
WO (1) WO2019186276A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
JP7170316B2 (en) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド Tau immunotherapy
KR102471787B1 (en) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 Tau recognition antibody
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies recognizing tau
CU20210073A7 (en) 2019-03-03 2022-04-07 Prothena Biosciences Ltd ANTIBODIES THAT BIND WITHIN THE CDRS-DEFINED MICROTUBULE-BINDING REGION OF TAU
AU2020345110A1 (en) 2019-09-09 2022-03-24 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
CN117043183A (en) * 2020-12-16 2023-11-10 沃雅戈治疗公司 TAU binding compounds
JP2024509683A (en) * 2021-02-19 2024-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-PT217 TAU antibody
CN117003863A (en) * 2022-04-28 2023-11-07 厦门大学 Antibodies to p-tau 217 and uses thereof
CN114778856B (en) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 Phosphorylated tau protein detection kit
WO2024040212A2 (en) * 2022-08-19 2024-02-22 Staidson Biopharma Inc. Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof
CN117624351B (en) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 Anti-human phosphorylated tau181 rabbit monoclonal antibody and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
WO2013041962A1 (en) * 2011-09-19 2013-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US20140234214A1 (en) * 2013-01-18 2014-08-21 Ipierian, Inc. Methods of Treating a Tauopathy

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2141216A1 (en) 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
WO1997004801A1 (en) 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
ATE234635T1 (en) 1995-12-22 2003-04-15 Bristol Myers Squibb Co COUPLERS CONTAINING BRANCHED HYDRAZONE GROUPS
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (en) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
ATE391781T1 (en) 2002-07-12 2008-04-15 Axon Neuroscience TRANSGENIC ANIMAL WHICH EXPRESSES THE TRUNKED ALZHEIMER TAU PROTEIN
KR101186210B1 (en) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
CA2511599A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
SI3221349T1 (en) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
US20190315886A1 (en) * 2016-02-05 2019-10-17 Jiangsu Hengrui Medicine Co., Ltd. Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
WO2013041962A1 (en) * 2011-09-19 2013-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US20140234214A1 (en) * 2013-01-18 2014-08-21 Ipierian, Inc. Methods of Treating a Tauopathy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARTHÉLEMY NICOLAS R ET AL: "HIGHLY SPECIFIC CSF TAU HYPERPHOSPHORYLATION ON T217 OCCURS SIMULTANEOUSLY WITH AMYLOIDOSIS", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, vol. 13, no. 7, 17 July 2017 (2017-07-17), XP085216689, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2017.06.911 *
CHRISTOPHER M. ACKER ET AL: "Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models", NEUROBIOLOGY OF AGING, vol. 34, no. 1, 1 January 2013 (2013-01-01), US, pages 338 - 350, XP055621423, ISSN: 0197-4580, DOI: 10.1016/j.neurobiolaging.2012.05.010 *
DAVID SINGER ET AL: "Characterization of Phosphorylation Dependent Antibodies To Study the Phosphorylation Status of the Tau Protein", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, vol. 11, no. 4, 1 December 2005 (2005-12-01), NL, pages 279 - 289, XP055546131, ISSN: 1573-3149, DOI: 10.1007/s10989-005-9269-4 *
HIROTAKA YOSHIDA ET AL: "Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38? or JNK2 in the presence of heparin generates the AT100 epitope", JOURNAL OF NEUROCHEMISTRY, vol. 99, no. 1, 1 October 2006 (2006-10-01), GB, pages 154 - 164, XP055621450, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2006.04052.x *
JAN TORLEIF PEDERSEN ET AL: "Tau immunotherapy for Alzheimer's disease", TRENDS IN MOLECULAR MEDICINE, vol. 21, no. 6, 1 June 2015 (2015-06-01), GB, pages 394 - 402, XP055307560, ISSN: 1471-4914, DOI: 10.1016/j.molmed.2015.03.003 *
JERE E. MEREDITH JR. ET AL: "Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease", PLOS ONE, vol. 8, no. 10, 7 October 2013 (2013-10-07), pages e76523, XP055395393, DOI: 10.1371/journal.pone.0076523 *
NICOLAS R. BARTHÉLEMY ET AL: "Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-[beta] pathology", BIORXIV, 30 November 2017 (2017-11-30), pages 1 - 20, XP055621444, Retrieved from the Internet <URL:https://www.biorxiv.org/content/biorxiv/early/2017/11/30/226977.full.pdf> [retrieved on 20190912], DOI: 10.1101/226977 *

Also Published As

Publication number Publication date
CN112236452A (en) 2021-01-15
WO2019186276A2 (en) 2019-10-03
AU2019244481A1 (en) 2020-10-01
MX2020009991A (en) 2020-10-14
IL277577A (en) 2020-11-30
BR112020018868A2 (en) 2021-01-26
WO2019186276A8 (en) 2020-10-15
EP3774887A2 (en) 2021-02-17
JP2021520777A (en) 2021-08-26
RU2020135052A (en) 2022-04-29
CA3095443A1 (en) 2019-10-03
SG11202008098TA (en) 2020-10-29
KR20200144551A (en) 2020-12-29

Similar Documents

Publication Publication Date Title
WO2019186276A3 (en) Antibody-based methods of detecting and treating alzheimer&#39;s disease
WO2017136820A3 (en) Fabs-in-tandem immunoglobulin and uses thereof
CY1122458T1 (en) ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2018089508A3 (en) Anti-cd47 antibodies
MY183989A (en) Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer&#39;s disease
GEP20217222B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
CR20210492A (en) ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2018031490A3 (en) Anti-ox40 binding proteins
MX354662B (en) Phosphospecific antibodies recognising tau.
MX356800B (en) Humanized tau antibody.
BR112016030183A2 (en) antibodies and antigen binding fragments that specifically bind to the microtubule-associated tau protein
WO2007050359A3 (en) Anti-addl monoclonal antibody and use thereof
MX2018016183A (en) Pd-l1-specific antibodies and methods of using the same.
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
EP3883602A4 (en) Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
MX338640B (en) Anti-addl monoclonal antibody and uses thereof.
EA201990895A1 (en) ANTIBODIES TO O1 AND OPTIONS OF THEIR APPLICATION
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
WO2017062496A3 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
WO2015160858A3 (en) Antigen binding proteins that bind wisp1
WO2021024133A3 (en) Biopharmacuetical compositions and related methods
WO2018026969A3 (en) Plazomicin antibodies and methods of use
MA52175A (en) ANTI-PFRH5 ANTIBODIES AND THEIR ANTIGEN BINDING FRAGMENTS

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020551506

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3095443

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019244481

Country of ref document: AU

Date of ref document: 20190327

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020018868

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019732436

Country of ref document: EP

Effective date: 20201028

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19732436

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112020018868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200916